PT1286671E - Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan - Google Patents

Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan

Info

Publication number: PT1286671E
Authority: PT; Portugal
Prior art keywords: irinotecan; treatment; compositions; cancer; talidomida
Prior art date: 2000-05-15

Application number

PT01935372T

Other languages

English (en)

Inventor

Rangaswamy Govindarajan

Andrew Zeitlin

Original Assignee

Univ Arkansas

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-15

Filing date

2001-05-10

Publication date

2006-08-31

2001-05-10 Application filed by Univ Arkansas, Celgene Corp filed Critical Univ Arkansas

2006-08-31 Publication of PT1286671E publication Critical patent/PT1286671E/pt

Links

UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 title abstract 4
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 4
229960004768 irinotecan Drugs 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
229960003433 thalidomide Drugs 0.000 abstract 3
206010009944 Colon cancer Diseases 0.000 abstract 2
208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

PT01935372T 2000-05-15 2001-05-10 Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan PT1286671E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20414200P	2000-05-15	2000-05-15

Publications (1)

Publication Number	Publication Date
PT1286671E true PT1286671E (pt)	2006-08-31

Family

ID=22756801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01935372T PT1286671E (pt)	2000-05-15	2001-05-10	Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan

Country Status (12)

Country	Link
US (2)	US6914067B2 (pt)
EP (1)	EP1286671B1 (pt)
JP (1)	JP4679028B2 (pt)
AT (1)	ATE322265T1 (pt)
AU (2)	AU2001261473B2 (pt)
CA (1)	CA2408710C (pt)
DE (1)	DE60118547T2 (pt)
DK (1)	DK1286671T3 (pt)
ES (1)	ES2261415T3 (pt)
NZ (1)	NZ522766A (pt)
PT (1)	PT1286671E (pt)
WO (1)	WO2001087306A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6881420B2 (en) *	2000-06-23	2005-04-19	Teva Pharmaceutical Industries Ltd.	Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2005501840A (ja) *	2001-07-23	2005-01-20	エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト	癌の改良された治療のための手段および方法
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en)	2002-10-15	2008-03-19	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7230012B2 (en) *	2002-11-14	2007-06-12	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) *	2002-11-14	2015-04-14	Celgene Corporation	Pharmaceutical compositions and dosage forms of thalidomide
US6987012B2 (en) *	2003-06-11	2006-01-17	Ultra Biotech Limited	Biological compositions and methods for treatment of colorectal cancer
EA200600921A1 (ru) *	2003-11-06	2006-10-27	Селджин Корпорейшн	Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
KR101462825B1 (ko)	2004-05-03	2014-11-21	헤르메스 바이오사이언스, 인코포레이티드	약물 전달에 유용한 리포좀
US8658203B2 (en)	2004-05-03	2014-02-25	Merrimack Pharmaceuticals, Inc.	Liposomes useful for drug delivery to the brain
US7994186B2 (en) *	2005-04-18	2011-08-09	Kabushiki Kaisha Yakult Honsha	Pharmaceutical compositions containing camptothecins
JP2008540585A (ja) *	2005-05-19	2008-11-20	プロメティック・バイオサイエンスィズ・インコーポレーテッド	転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法
EP1946114A4 (en) *	2005-09-21	2010-05-26	Ccc Diagnostics Llc	COMPREHENSIVE DIAGNOSTIC TESTS FOR PERSONAL ANTIBODY CHEMOTHERAPY (PAC)
US20070219825A1 (en) *	2005-11-23	2007-09-20	Maetzold Derek J	Method of managing and reducing side effects associated with exposure to a drug
US7723301B2 (en) *	2007-08-29	2010-05-25	The Board Of Trustees Of The University Of Arkansas	Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090137631A1 (en) *	2007-11-22	2009-05-28	National Yang-Ming University	Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20120045433A1 (en) *	2010-08-17	2012-02-23	Kapil Dhingra	Combination therapy
US8709419B2 (en)	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en)	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
AU2013202947B2 (en)	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10098813B2 (en)	2014-09-03	2018-10-16	Sun Pharmaceutical Industries Limited	Perfusion dosage form
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en)	2015-08-20	2020-03-30	Ipsen Biopharm Ltd	Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en)	2015-08-21	2021-03-17	Ipsen Biopharm Ltd.	Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en)	2015-10-16	2025-09-19	Ipsen Biopharm Ltd	Stabilizing camptothecin pharmaceutical compositions
CN109069342A (zh)	2016-02-09	2018-12-21	太阳医药工业有限公司	灌注系统
RU2761953C2 (ru)	2016-11-02	2021-12-14	Ипсен Биофарм Лтд.	Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
JP7536085B2 (ja) *	2019-08-19	2024-08-19	メルスナムローゼフェンノートシャップ	Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6019790A (ja)	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
AU1531492A (en)	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5643915A (en)	1995-06-06	1997-07-01	Andrulis Pharmaceuticals Corp.	Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en)	1995-06-07	1997-08-05	Andrulis Pharmaceuticals	Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
WO1998037892A1 (en) *	1997-02-27	1998-09-03	Pharmacia & Upjohn Company	Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea

2001
- 2001-05-10 JP JP2001583774A patent/JP4679028B2/ja not_active Expired - Fee Related
- 2001-05-10 WO PCT/US2001/015326 patent/WO2001087306A2/en not_active Ceased
- 2001-05-10 AU AU2001261473A patent/AU2001261473B2/en not_active Ceased
- 2001-05-10 DK DK01935372T patent/DK1286671T3/da active
- 2001-05-10 AT AT01935372T patent/ATE322265T1/de active
- 2001-05-10 DE DE60118547T patent/DE60118547T2/de not_active Expired - Lifetime
- 2001-05-10 CA CA2408710A patent/CA2408710C/en not_active Expired - Fee Related
- 2001-05-10 ES ES01935372T patent/ES2261415T3/es not_active Expired - Lifetime
- 2001-05-10 NZ NZ522766A patent/NZ522766A/en not_active IP Right Cessation
- 2001-05-10 EP EP01935372A patent/EP1286671B1/en not_active Expired - Lifetime
- 2001-05-10 AU AU6147301A patent/AU6147301A/xx active Pending
- 2001-05-10 PT PT01935372T patent/PT1286671E/pt unknown
- 2001-05-14 US US09/853,619 patent/US6914067B2/en not_active Expired - Fee Related
2005
- 2005-05-11 US US11/126,315 patent/US7479499B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1286671A2 (en)	2003-03-05
EP1286671B1 (en)	2006-04-05
JP2003533483A (ja)	2003-11-11
DK1286671T3 (da)	2006-07-17
WO2001087306A8 (en)	2002-10-03
WO2001087306A2 (en)	2001-11-22
US20050203060A1 (en)	2005-09-15
ATE322265T1 (de)	2006-04-15
AU2001261473B2 (en)	2006-09-14
DE60118547T2 (de)	2007-02-01
US20020035091A1 (en)	2002-03-21
HK1053975A1 (en)	2003-11-14
CA2408710C (en)	2010-01-26
CA2408710A1 (en)	2001-11-22
DE60118547D1 (de)	2006-05-18
NZ522766A (en)	2005-09-30
AU6147301A (en)	2001-11-26
US7479499B2 (en)	2009-01-20
JP4679028B2 (ja)	2011-04-27
ES2261415T3 (es)	2006-11-16
US6914067B2 (en)	2005-07-05

Publication	Publication Date	Title
AU6147301A (en)	2001-11-26	Compositions and methods for the treatment of colorectal cancer
MXPA02011218A (es)	2004-08-19	Composiciones y metodos para el tratamiento de cancer.
AR028296A1 (es)	2003-04-30	Metodos sinergisticos y composiciones para el tratamiento del cancer
WO2004052280A3 (en)	2004-08-12	Anti-angiogenic compounds and their use in cancer treatment
NO20054988D0 (no)	2005-10-26	Preparater og metoder for behandling av cancer
WO2004030627A3 (en)	2004-07-01	Synergistic methods and compositions for treating cancer
HK1042244A1 (zh)	2002-08-09	包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物
DK1169059T3 (da)	2006-02-27	Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BR0316170A (pt)	2005-09-27	Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
WO2004093831A3 (en)	2006-04-06	Cytokine-expressing cellular vaccine combinations
NO20050807L (no)	2005-02-15	Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
IL174965A0 (en)	2006-08-20	SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2005018677A3 (en)	2006-05-26	Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
TW200509949A (en)	2005-03-16	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2002040702A3 (en)	2004-01-08	Methods for the treatment of cancer and other diseases and methods of developing the same
WO2002039994A3 (en)	2003-08-21	Methods for the treatment and prevention of urinary stone disease
ATE344670T1 (de)	2006-11-15	Synergistische kombination zur behandlung von kolorektalkarzinom
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
PL368971A1 (en)	2005-04-04	Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
WO2002094189A3 (en)	2003-04-10	Compositions and methods for treating or preventing convulsions or seizures
PL368271A1 (en)	2005-03-21	Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
DE60213116D1 (de)	2006-08-24	Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
MX2025004758A (es)	2025-06-02	Compuestos y su uso para el tratamiento de hemoglobinopatias
PL357179A1 (en)	2004-07-26	Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
ATE344664T1 (de)	2006-11-15	Verbesserte methode zur eradikation von helicobacter pylori